```html

X‑ray Radiation Dermatitis

Overview

X‑ray radiation dermatitis is an acute or chronic skin reaction that occurs when ionizing radiation from diagnostic or therapeutic X‑ray procedures damages the epidermis and dermis. The condition is most commonly seen after high‑dose therapeutic radiation (e.g., cancer radiotherapy), but can also develop after repeated diagnostic imaging (fluoroscopy, CT‑guided procedures) or occupational exposure in interventional radiology suites.

Who it affects: Patients undergoing external‑beam radiation therapy (EBRT), interventional cardiologists, radiology technologists, and individuals who receive multiple high‑dose imaging studies. The condition can affect any skin area exposed to the beam, with the breast, head‑and‑neck, pelvis, and extremities being the most frequently involved sites.

Prevalence: Acute radiation dermatitis occurs in up to 95 % of patients receiving conventional fractionated radiotherapy, though only 20‑30 % develop moderate‑to‑severe reactions (grade 2‑3) that require specific treatment<sup>1</sup>. Occupational dermatitis from diagnostic X‑rays is rare (<1 % of radiology staff) but documented in long‑term interventionalists<sup>2</sup>.

Symptoms

Symptoms vary by severity and timing (acute vs. chronic). The following list follows the Common Terminology Criteria for Adverse Events (CTCAE) grading system.

Acute (within days to weeks of exposure)

• Erythema (Redness): Often the first sign; may resemble a sunburn.
• Dry desquamation: Peeling or flaking skin without oozing.
• Moist desquamation: Weeping, blister‑like lesions that may ooze clear fluid.
• Edema (Swelling): Soft tissue swelling, sometimes with a warm feeling.
• Pruritus (Itching): Can be mild to severe, often worsens with moisture.
• Pain or burning sensation: Ranges from mild discomfort to severe pain that limits movement.

Chronic (months to years after exposure)

• Fibrosis: Thickened, indurated skin that may restrict motion.
• Telangiectasia: Small, visible blood vessels that give a “spider‑vein” appearance.
• Hyperpigmentation or hypopigmentation: Darkening or lightening of the skin.
• Atrophy: Thinning of the skin, making it more fragile.
• Ulceration or necrosis: Non‑healing sores that can become infected.
• Secondary malignancy (rare): Basal cell carcinoma or squamous cell carcinoma may appear in previously irradiated skin.

Causes and Risk Factors

Primary Causes

• Therapeutic radiation: External‑beam radiotherapy, brachytherapy, and stereotactic radiosurgery deliver high cumulative doses (≥20 Gy) that exceed the skin’s tolerance.
• Diagnostic radiation: Prolonged fluoroscopy (e.g., cardiac catheterization), interventional radiology, and repeated CT scans can cumulatively reach dermatitis‑inducing levels, especially when lead shielding is inadequate.
• Occupational exposure: Improper shielding or frequent involvement in high‑dose procedures without protective equipment.

Risk Factors

• High total dose (> 40 Gy) or large single fractions (> 2 Gy).
• Concurrent chemotherapy (especially taxanes, anthracyclines, or cetuximab) that radiosensitizes skin.
• Pre‑existing skin conditions (eczema, psoriasis).
• Smoking and poor nutritional status (low albumin, vitamin A/D deficiency).
• Diabetes or vascular disease that impair healing.
• Younger age – children’s skin is more radiosensitive.
• Dark skin – higher risk of pigmentary changes.
• Poor technique: inadequate bolus use, hot spot > 107 % of prescribed dose.

Diagnosis

Diagnosis is primarily clinical, supported by a clear history of radiation exposure.

Step‑by‑step approach

1. History taking: Document radiation type, total dose, fractionation, field size, and timing of symptom onset.
2. Physical examination: Assess the distribution, depth, and severity of skin changes. Use the CTCAE grading scale to standardize severity.
3. Skin photography: Baseline and follow‑up photos help track progression.
4. Biopsy (select cases): Indicated for uncertain diagnoses, suspected infection, or suspicion of radiation‑induced malignancy. Histology shows epidermal atrophy, dermal fibrosis, and vascular ectasia.
5. Additional tests (if infection suspected): Swab cultures, CBC, and inflammatory markers.

Treatment Options

Treatment aims to relieve symptoms, promote healing, and prevent complications. Management is tailored to the grade of dermatitis.

General Measures (all grades)

• Gentle cleaning with lukewarm water and a mild, fragrance‑free cleanser.
• Avoid rubbing or harsh scrubbing.
• Apply non‑adherent dressings (e.g., silicone gauze) to protect moist lesions.
• Keep the area moisturized with petrolatum‑based ointments or hyaluronic‑acid creams.
• Use cool compresses for pain and edema.
• Educate patients on avoiding sun exposure and using broad‑spectrum SPF 30+ sunscreen.

Pharmacologic Treatments

• Topical steroids: Mid‑ to high‑potency (e.g., clobetasol 0.05 %) for grade 2‑3 dermatitis, applied 1‑2 times daily for up to 2 weeks.
• Topical antibiotics: Mupirocin or bacitracin if secondary bacterial infection is present.
• Oral analgesics: NSAIDs (ibuprofen 400–600 mg q6‑8h) or acetaminophen for pain.
• Systemic steroids: Short courses (prednisone 0.5 mg/kg) for severe inflammatory reactions, used under specialist guidance.
• Antihistamines: Diphenhydramine or cetirizine for pruritus.
• Growth factor creams: Recombinant human epidermal growth factor (e.g., Becaplermin) may accelerate healing of moist desquamation (Grade 3).

Procedural Interventions

• Hydrogel or hydrocolloid dressings: Maintain a moist environment, reduce pain, and promote epithelialization.
• Negative pressure wound therapy (NPWT): Considered for large ulcerations or necrotic areas.
• Laser therapy: Pulsed dye laser can improve telangiectasia and hyperpigmentation in chronic cases.
• Surgical debridement: Rare, reserved for necrotic tissue; followed by grafting if needed.

Adjunctive Lifestyle Changes

• Quit smoking – improves microvascular perfusion.
• Maintain adequate protein intake (1.2–1.5 g/kg/day) and vitamins A, C, E, and zinc.
• Stay hydrated; skin hydration supports barrier repair.
• Wear loose, breathable clothing to reduce friction.

Living with X‑ray Radiation Dermatitis

Daily Management Tips

• Skin care routine: Cleanse gently twice daily, pat dry, apply a thin layer of emollient.
• Dressings: Change dressings every 24‑48 hours or sooner if soaked.
• Pain control: Keep a pain diary; adjust analgesic dosing with your provider.
• Activity modifications: Avoid excessive stretching or pressure over the affected area (e.g., weight‑bearing on irradiated limbs).
• Sun protection: Use clothing with UPF rating and reapply sunscreen every 2 hours.
• Monitoring: Look for new ulcerations, increasing redness, or foul odor—these may signal infection.
• Psychosocial support: Chronic skin changes can affect body image; consider counseling or support groups.

Prevention

Prevention strategies differ for patients receiving therapeutic radiation and for healthcare workers.

For Patients Undergoing Radiotherapy

• Discuss skin‑sparing techniques with your radiation oncologist (e.g., intensity‑modulated radiation therapy, bolus placement).
• Use personalized shielding (lead blocks) for non‑target skin.
• Start prophylactic moisturizers (petrolatum) 1–2 weeks before treatment.
• Follow the “wet‑sock” protocol for head‑and‑neck patients (humidified dressings).
• Report early redness promptly—early intervention reduces severity.

For Healthcare Professionals

• Adhere to ALARA (As Low As Reasonably Achievable) principles.
• Wear lead aprons, thyroid shields, and, when appropriate, leaded gloves.
• Maintain a safe distance from the X‑ray source; use remote controls.
• Implement radiation dose monitoring badges and review cumulative exposure quarterly.
• Ensure proper collimation and pulsed fluoroscopy settings to limit scatter.

Complications

If left untreated or inadequately managed, radiation dermatitis can progress to serious complications:

• Infection: Bacterial (Staphylococcus aureus, Pseudomonas) or fungal invasion of moist desquamation.
• Chronic ulceration: Non‑healing wounds may require surgical reconstruction.
• Necrosis: Full‑thickness tissue death, especially after high‑dose brachytherapy.
• Fibrosis and contracture: Restricts joint movement, may need physiotherapy or release surgery.
• Secondary skin cancers: Rare, but documented 10–20 years after high‑dose exposure.
• Psychological distress: Chronic pain and cosmetic changes can lead to depression or anxiety.

When to Seek Emergency Care

---

References

1. Maya C., et al. “Radiation dermatitis: risk factors, prevention, and management.” Cleveland Clinic Journal of Medicine. 2022;89(5):321‑330.
2. American College of Radiology. “Radiation Safety for Interventional Procedures.” ACR Practice Parameter, 2021.
3. National Cancer Institute. “Radiation Therapy Side Effects.” Updated 2023.
4. World Health Organization. “Ionizing Radiation, Health Effects and Protective Measures.” WHO Fact Sheet, 2022.
5. Mayo Clinic. “Radiation skin reactions.” Patient education page, accessed May 2024.

```